Ketamina para el tratamiento de depresión

Abstract

Introduction: Depression is a significant problem in public health systems worldwide, with high rates. There are several treatment alternatives available, and currently, the action of ketamine, an ultra-short-acting dissociative anesthetic, is highlighted. At low doses, it could be an effective and excellent alternative due to its positive results in alleviating depressive symptoms in a matter of hours, especially in more complex cases. Literature Review: The antagonistic effect of ketamine occurs in the N-methyl-D-aspartate (NMDA) glutamate receptor, causing an increase in the presynaptic release region. It is administered intravenously as a single dose of 0.5 mg/kg, as a bolus or infusion over 40 to 100 minutes. Its onset of action is 1 to 4 hours post-administration, lasting 3 to 6 weeks. Ketamine is extremely useful, particularly in cases of resistance to conventional depression treatments, and both the dosage and the route of administration trigger the adverse effects of the medication. Conclusions: Based on the studies found, conclude that the use of ketamine at doses of 0.5mg/kg, especially in cases of severe depression and suicidal ideation, is effective. Its use is safe and is approved by the FDA with the necessary guidelines to prevent adverse and unwanted effects in patients with cardiovascular diseases.